Related Experiment Video
Updated: Aug 10, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Abstract:
Retrospective evaluation of cell-mediated tumor-associated immunity in patients with prostatic cancer before and after the receipt of non hormonal or hormonal therapy disclosed that patients receiving hormonal therapy, i. e., orchiectomy and/or oestrogen, possessed significantly lower levels. The potential clinical relevancy of the suggested immunosuppressive effects of hormonal therapy on tumor-host responsiveness is considered in view of the present and previous observations.
Related Concept Videos
The Tumor Microenvironment
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

